TriClip™ Clinical Data

PROVEN SAFETY IN
TRICUSPID REGURGITATION
THERAPY

IMPLANT SUCCESS RATE1

PROVEN SAFETY AND EFFECTIVENESS

0

Procedural
deaths1

0

Procedural
strokes1

0

Conversion
to surgery1

90.5%

Acute procedural
success rate1

0%

In-hospital
mortality1

0%

Mortality
at 30 days1
  • TRILUMINATE™ CLINICAL TRIAL SHOWS EFFECTIVE AND DURABLE OUTCOMES

    DURABLE REDUCTION IN TRICUSPID REGURGITATION

    The proportion of subjects with moderate or less TR increased from 8% at baseline to 70% at 1 year.

  • TRILUMINATE™ CLINICAL TRIAL SHOWS SIGNIFICANT HEALTH-RELATED IMPROVEMENTS

    CONTINUED IMPROVEMENTS IN NYHA

  • TRICLIP™ DEMONSTRATES HIGH SAFETY PROFILE

    HIGH SURVIVAL IN A FRAGILE PATIENT POPULATION

    LOW RATES OF ADVERSE EVENTS

  • PATIENTS IN TRILUMINATE™ TRIAL SAW SIGNIFICANT REDUCTION IN HOSPITALIZATIONS

    REDUCED HOSPITALIZATION RATE

    A 40% reduction in hospitalization rate was observed after tricuspid regurgitation reduction following TriClip Implant.

    PROCEDURAL SUCCESS PREDICTIVE OF MORTALITY AND HEART FAILURE HOSPITALIZATIONS AT 1 YEAR

    Reduction to moderate or less TR resulted in a three-fold decrease in mortality or heart failure hospitalizations at 1 year.

MAT-2006556 v2.0

References
  1. Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study [published online ahead of print November 7, 2019]. Lancet. 2019;394(10213):2002-2011. doi:10.1016/S0140-6736(19)32600-5.
  2. Lurz P, von Bardeleben RS, Sitges M, et al. Percutaneous Edge-to-Edge Repair for Tricuspid Regurgitation: 1-Year Outcomes from the TRILUMINATE Trial. Presented at PCR e-Course 2020.

This site uses cookies to improve your experience.

To find out more please read our Privacy and Cookies policy.

Ok

Sign up

Receive updates from Abbott Structural Heart

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

YOU ARE ABOUT TO LEAVE
www.structural­heart­solutions.com

You are now leaving www.structuralheartsolutions.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.